Chem Rx

Ortho-McNeil-Janssen Pharmaceuticals offers a range of health care products for the treatment of several infectious diseases, as well as pain management. The company s sister concern Ortho-McNeil, which serves primary care hospitals and other care facilities. Ortho-McNeil s products are available under the DURAGESIC, LEVAQUIN, FLOXIN, NIZORAL and PROPULSID brads. The company provides injections, shampoos, caplets, tablets and capsules. Ortho-McNeil offers the ACIPHEX product, which is used of the treatment of heartburn and other symptoms associated with acid reflux disease. The company additionally provides the DORIBAX product for patients with gram negative infections. Ortho-McNeil undertakes several research and development activities.

Daiichi Sankyo Pharma Dev, based in Edison, NJ, is dedicated to advancing healthcare through innovative medicines and a compassionate approach to patient care. The company is committed to creating essential treatments for diverse health needs, particularly in oncology, by harnessing cutting-edge science and technology. With a focus on fostering an inclusive and diverse community of collaborators, Daiichi Sankyo leverages unique expertise to develop high-quality solutions for patients. Their advancements include the breakthrough ENHERTU treatment, demonstrated to significantly improve outcomes for those with HER2 positive metastatic breast cancer, highlighting the company's relentless dedication to transforming patient journeys. Generated from the website

Ipsen is a mid-sized global biopharmaceutical company based in Basking Ridge, NJ, dedicated to improving patients' lives through research, innovation, and the development of transformative medicines in Oncology, Rare Disease, and Neuroscience. With a focus on areas of high unmet medical need, Ipsen accelerates momentum by rapidly boosting its pipeline to bring innovative medicines to patients. Guided by patient outcomes and a commitment to collaboration and excellence, Ipsen leverages its global reach and R&D firepower to develop the next generation of medicines. Through its Ipsen Way of Being and Generation Ipsen ESG responsibility strategy, the company is shaping a more sustainable future while making a real impact for people living with high unmet medical needs.Generated from the website